📝 Publication News: A new manuscript in the Journal of the Advanced Practitioner in Oncology (#JADPRO) discusses the mechanism of action, clinical and safety data, dosing and administration information, and clinical practice implications of our treatment for certain lower-risk #MDS patients with anemia. Read more: https://lnkd.in/eKf73A34
Geron Corporation
Biotechnology Research
Foster City, California 19,345 followers
Changing lives by changing the course of blood cancer.
About us
Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients. To learn more, visit www.geron.com. Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/
- Website
-
http://www.geron.com
External link for Geron Corporation
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Foster City, California
- Type
- Public Company
- Founded
- 1992
- Specialties
- Oncology, Hematologic Malignancies, and Telomerase Inhibition
Locations
-
Get directions
919 E Hillsdale Blvd
Foster City, California 94404, US
Employees at Geron Corporation
Updates
-
A well-deserved honor. Congratulations to our colleague Shannon Odam, named The Leukemia & Lymphoma Society's Silicon Valley Visionary of the Year! Shannon’s dedication—rooted in personal experience and a passion to help others, led her to rally her community and raise vital funds for research and patient support. We’re proud to celebrate her incredible impact and the difference she’s making for people affected by blood cancer. #TeamGeron
-
-
Spotted in Lisbon 🇵🇹: Caroline Pak and Natasha Moningka, Ph.D. representing #TeamGeron at #iwMDSMPN25! This annual workshop convenes leading scientists and clinicians in #MDS and MPNs to share insights, spark ideas and advance progress for patients. As Silver Supporters, we were honored to stand behind this vibrant community and its mission to move the science forward!
-
-
Meet Linda. She’s been living with LR-#MDS for several years. In her own words, she talks about what it’s like to face a disease few understand — and how her outlook has grown from uncertainty to acceptance and hope. We’re so grateful to Linda for courageously sharing her story. By lending her voice, she’s helping others feel seen and less alone. You can now find Linda’s story on our new patients’ page, created to shine a light on the real experiences of people living with MDS. Their voices inspire us every day to keep pushing forward in research, care and support. 🧡 Watch Linda’s full story and explore more: https://lnkd.in/eDguTWS2
-
Meet Jeff Ryel, Senior Director of Clinical Operations. With decades of experience in clinical research, Jeff is known for his clarity, compassion, and strategic mindset. At Geron, he plays a vital role in moving innovative therapies forward — always with patients at the center, wherever they are in the world. His day-to-day? Fast-paced, complex, and deeply meaningful. During #PrideMonth, Jeff reflects on Pride as more than a celebration. It’s a continued commitment to authenticity, inclusion, and community, and a reminder of the importance of creating spaces where everyone feels supported and empowered to show up fully as themselves. We’re honored to spotlight Jeff, not just for the work he leads, but for the values and leadership he brings to #TeamGeron.
-
Behind every poster at #EHA2025 was a story of progress. We were proud to share new data from the IMerge Phase 3 study, including additional analyses using TwiTR (Time Without Transfusion Reliance), a novel endpoint providing deeper insights into patient-centric outcomes. If you couldn’t make it in person, see our press release announcing presentations at EHA: https://lnkd.in/eZUYs2Tt
-
-
Spotted at #EHA2025: A sweet tribute to the power of scientific discovery. During our time in Milan, chocolate coins honoring Alfred Nobel were found throughout the convention center. Did you know that Geron has a legacy of Nobel Prize-winning science, grounded in decades of telomere research? Our history is a testament to what long-term scientific investment can achieve. Explore our timeline: https://lnkd.in/gem-hqzF
-
-
Momentum. Collaboration. Breakthrough science. #EHA2025 delivered all of it – and #TeamGeron was proud to be right in the middle of it. From advancing the understanding of telomerase inhibition to connecting with the global #hematology community, we leave Milan more energized than ever. 🎬 A look back at a few unforgettable moments – with more to come.
-
Day 2 at #EHA2025 and the momentum is strong! If you’re in Milan, keep an eye out for #TeamGeron. We’re excited to connect, share ideas and talk about where #hematology #oncology is headed next. Swipe through to see the team in action – and if you see us around, don’t be shy. Come say hello! 👋
-
-
Ciao from Milan! ☕ 🇮🇹 #TeamGeron has officially jumped into #EHA2025! We’re serving up six new posters deepening the understanding of how telomerase inhibition may impact treatment in hematologic malignancies. Join our Chief Medical Officer Dr. Faye Feller and the rest of the team in the poster hall to explore how our work is helping to advance the field and reshape the future #BloodCancer care – one cup (and data point) at a time. Let’s move the science forward – together.